Erli 10mg Tablets (20s)

Description

Erli 10mg Tablets contain empagliflozin, an oral medicine used to help improve blood-glucose control in adults with type 2 diabetes. It may be prescribed alone or with other diabetes medicines alongside diet and exercise.

• Manufacturer Name: Pharmevo
• Drug Class: Sodium-glucose cotransporter-2 (SGLT2) inhibitor
• Dosage Form: Immediate-Release Tablet
• Storage: Store at room temperature, preferably between 20°C and 25°C. Keep in the original packaging, protected from moisture, heat, and direct light, and out of reach of children.
• Pack Size: Pack of 20 Tablets

Erli 10mg Tablets (20s) Available Online in Pakistan

Dwatson offers Erli 10mg Tablets (20s) at Rs. 702.4, with fast, discreet delivery across Pakistan.

Ingredients

• Empagliflozin 10 mg

Benefits

• Improves blood-glucose control in adults with type 2 diabetes mellitus.
• May be used alone or together with diet, exercise, and other antidiabetic medicines.
• May provide cardiovascular, heart-failure, or kidney-related benefits when specifically prescribed for appropriate patients.

Usage & Safety

For Adult

• The usual starting dose is 10 mg once daily, taken in the morning, with or without food.
• For additional blood-glucose control, a healthcare professional may increase the dose to 25 mg once daily when appropriate and tolerated.
• Maintain adequate fluid intake unless a healthcare professional has advised fluid restriction.
• Dosage selection should consider kidney function, hydration status, age, and other diabetes medicines.

For Children

• Safety and effectiveness for routine use in children and adolescents under 18 years have not been adequately established.
• Do not use in children unless specifically prescribed and supervised by a specialist.
• No general pediatric weight-based dose is established for this product.

Side Effects

• Common effects may include increased urination, thirst, genital fungal infections, urinary tract infections, and symptoms related to volume depletion such as dizziness.
• Low blood glucose is more likely when used with insulin or sulfonylureas.
• Serious effects may include diabetic ketoacidosis, severe dehydration, low blood pressure, serious urinary or genital infections, and allergic reactions.
• Seek urgent medical attention for nausea, vomiting, abdominal pain, unusual tiredness, difficulty breathing, confusion, severe weakness, fever, or pain and swelling around the genital or perineal area.

Contraindications

• Do not use in patients with a known serious allergy or hypersensitivity to empagliflozin or any tablet ingredient.
• Not intended for treatment of type 1 diabetes or diabetic ketoacidosis.
• Use is generally unsuitable in patients receiving dialysis or with severe kidney impairment for blood-glucose control.
• Use cautiously in patients with dehydration, low blood pressure, recurrent urinary or genital infections, or a history of diabetic ketoacidosis.
• Temporarily discontinue and seek medical advice during major surgery, prolonged fasting, or serious acute illness when advised by a healthcare professional.

Precautions & Warnings

• Insulin and sulfonylureas may increase the risk of hypoglycemia; dose adjustment may be required.
• Diuretics and other medicines that lower blood pressure may increase the risk of dehydration, dizziness, or low blood pressure.
• Medicines or conditions that cause fluid loss, including vomiting, diarrhea, prolonged fasting, or excessive alcohol intake, may increase the risk of dehydration and ketoacidosis.
• Tell the healthcare professional about all prescription medicines, over-the-counter products, and supplements before use.
• It may be taken with or without food; maintain consistent hydration unless fluid restriction has been prescribed.

Pregnancy

• Do not use during pregnancy unless specifically directed by a healthcare professional; alternative treatment is generally preferred, particularly during the second and third trimesters.
• Inform the prescriber immediately if pregnancy occurs or is planned.
• Breastfeeding is generally not recommended during treatment because potential effects on the infant's developing kidneys cannot be excluded.